Latest / Chicago News Today | 2 Min News | The Daily News Now!
First Drug Targets Pancreatic Cancer Mutation | Chicago News
Pancreatic cancer just got a game-changing breakthrough: the FDA has approved daraxonrasib, the first drug to target the most common form of this deadly disease. This daily pill, now branded Rasonque, blocks a mutated protein responsible for tumor growth in 90% of cases — a feat scientists have chased for decades. In a pivotal trial, patients on the drug lived nearly twice as long — 13.2 months vs. 6.7 months with chemo — and with fewer severe side effects. Public attention surged after a former Senator shared how it eased his pain, prompting early access and accelerating the FDA’s approval…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.